In April 2025, AcuCort received its first order for Zeqmelit® from Unimedic Pharma for the Danish market, marking the start of the launch. Over the summer, distribution to Danish pharmacies commenced, and initial feedback from the market points to demand in line with the company's expectations.

"The summer sales have met our expectations and indicate strong market interest. Our Nordic distribution partner, Unimedic Pharma, has demonstrated great commitment and strong local presence - two crucial factors for a successful launch," says AcuCort CEO Jonas Jönmark.

The launch in Denmark marks the final step in the company's commercial establishment in the Nordic region, where Zeqmelit® is already available in Sweden, Norway and Finland. In June, AcuCort announced that it had signed two strategic letters of intent (LOIs) to support its international expansion. The first was with Lunatus for the Middle East and Gulf States, and the second with Glenmark Pharmaceuticals concerning Germany and five additional European countries. Negotiations on commercial terms are underway and are expected to be concluded this autumn.

For further information: 
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.